Elranatamab for treating relapsed and refractory multiple myeloma after 3 or more treatments

Final draft guidance

Final draft guidance (PDF 305 KB)

Committee papers (PDF 4.89 MB)

Public committee slides (PDF 355 KB)

Equality impact assessment (downloadable version) (PDF 128 KB)

Managed Access Agreement (PDF 378 KB)

Provisional stakeholder list (pre-referral) (MSWord 52 KB)

Draft guidance

Committee papers (PDF 5.85 MB)

Public committee slides (PDF 1.41 MB)

Equality and health inequalities assessment (downloadable version) (PDF 120 KB)

Draft consultation document (downloadable version) (PDF 211 KB)

Draft consultation document (online commenting)

Register of interests (PDF 162 KB)

Final scope (MSWord 39 KB)

Final stakeholder list (MSWord 80 KB)

Equality impact assessment (Scoping) (MSWord 22 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (MSWord 48 KB)

Draft matrix post referral (PDF 169 KB)

Draft scope post referral (PDF 189 KB)